# A Case of Severe Acute Pancreatitis Secondary to COVID-19 Infection in a 30-Year-Old Male Patient

Haidar Alwaeli<sup>1</sup>, Mahvesh Shabbir<sup>1</sup>, Mali Khamissi Sobi<sup>2</sup>, Karar Alwaeli<sup>3</sup>

1. Medical Education and Simulation, Richmond University Medical Center, New York, USA 2. Family Medicine, A+ Urgent Care Center, Atlanta, USA 3. Pharmacology and Therapeutics, Roseman University of Health Sciences, Henderson, USA

Corresponding author: Haidar Alwaeli, halwaeli@asu.edu

# Abstract

A 30-year-old male with no significant medical history presented to the emergency department with complaints of fever, two days of intermittent abdominal pain, dry cough, nausea, vomiting, four days of diarrhea, and worsening dyspnea. Initial evaluation revealed a fever of (102.5 F) and tachycardia (114/min) with hypoxia (SaO2: 84% on room air) and bilateral wheezing on lung auscultation. X-ray of the chest revealed bilateral and peripheral ground-glass and consolidative pulmonary opacities. CT scan of the abdomen was notable for interstitial edema, mild inflammatory changes, and homogenous enhancement of the pancreatic parenchyma. His COVID-19 test came positive, and he was admitted to the intensive-care unit. He was managed symptomatically, and improvement in his clinical condition was observed after three days of admission. This case highlights a possible association between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), abdominal pain secondary to acute pancreatitis, and the need for meticulous clinical evaluation in patients presenting with gastrointestinal complaints.

Categories: Internal Medicine, Gastroenterology, Infectious Disease Keywords: covid-19, coronavirus, pancreatitis, coronavirus disease 2019, covid-19-associated coagulopathy, stroke

and covid-19, covid-19 respiratory failure, prophylactic and therapeutic anticoagulation, covid-19 pneumonia

# Introduction

Pancreatitis is an inflammatory process involving the pancreas, which can be subdivided into two main categories: acute and chronic [1]. Acute pancreatitis is a common disease with a wide range of clinical presentation, from its low-risk symptoms to a severe and acute process of multiple organ failure and increased risk of morbidity and mortality [2]. Gallstones remain the most common cause of acute pancreatitis. However, other causes of both acute and chronic pancreatitis include heavy alcohol use, viral or parasitic infections, cancer, and trauma [3]. With the recent COVID-19 pandemic, we have seen a surge in hospital visits due to gastrointestinal symptoms. Gastrointestinal involvement, such as abdominal pain, diarrhea, nausea, and vomiting, have all been reported recently in the literature [4]. We report a rare case of COVID-19 infection with acute respiratory distress and pancreatitis.

# **Case Presentation**

A 30-year-old Middle Eastern male with a body mass index of 21.4 presented with fever, dry cough, nausea, abdominal pain, vomiting, four days of diarrhea, and worsening dyspnea. The patient reports that for the past week he has had watery diarrhea and has had a decrease in appetite. Two days prior, he began having intermittent abdominal pain that initially felt like excessive bloating pains but now progressed to be constant. The pain was located in the epigastric area and radiates to the back. Additionally, he reports the use of melatonin (2 mg PO QHS) for the past two days, for symptoms of insomnia. He denies a history of alcohol use, smoking, jaundice, pruritis, hemoptysis, melena, or hematochezia. Physical examination of the patient showed fever (102.5 F) and tachycardia (114/min) with hypoxia (SaO2: 84% on room air) and bilateral wheezing on lung auscultation. Abdominal examination revealed moderate distention with diffuse tenderness to superficial palpation, with no peritonitis signs. Admission laboratory workup is summarized in Table 1. Laboratory findings were pertinent for elevated lipase and amylase (lipase/amylase elevation > three times the upper limit of normal) with a slight elevation in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT). A posteroanterior chest X-ray revealed bilateral and peripheral groundglass and consolidative pulmonary opacities. Hepatitis viral serology for A, B, and C, and human immunodeficiency virus (HIV) were all negative. Moreover, the patient tested positive for COVID-19 by a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay.

Review began 11/14/2020 Review ended 11/18/2020 Published 11/26/2020

#### © Copyright 2020

Alwaeli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Cureus

| Laboratory evaluation at the independence of the i |  |            |
|--|--|------------|
| <table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>   | Laboratory evaluation at the time of admission (reference ranges of laboratory data are included in parentheses) |            |
| <table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>   | Hematocrit (36.7-46.4%)  | 37.8%      |
| <table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>   | Hemoglobin (12.5-15.7 g/dL)  | 14.5 g/dL  |
| <table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>   | Total leukocyte count (3,800-11,000)   | 5,480/ uL  |
| Total neutrophilsSi%LymphocytesS%MonocytesS%FosinophilsS%Patelets (14,000-40,000/µL)S%Total bilrubin (s 1.2 mg/dL)Sm/dLTotal bilrubin (s 0.25 mg/dL)Sm/dLSerum aspartate aminotransferase (AST) (13-SS L)Sm/dLAlanine aminotransferase (AST) (13-SS L)Sm/dLAlanine phosphatase (A-GO L)Sm/dLTigyteride (s 10 mg/dL)Sm/dLLipase (s 20 U/L)Sm/dLLipase (s 20 U/L)Sm/dLAnyase (20-L)Sm/dLLipase (s 20 U/L)Sm/dLLipase (s 20 U/L)Sm/dLLipa   | Band neutrophils   | 2%         |
| IqnphoqtesSelfMonocytes9kRonocytes9kBoinophilsScionophilsPatelet (14,000-400,004,000,000,000,000,000,000,00  | Total neutrophils  | 51%        |
| Monocytes9%Eosinophils2%Pateles (140,000-000/LL)52,000/LLTotal bilrubin (s 1.2 mg/dL)0mg/dLDirect bilrubin (s 0.25 mg/dL)012 mg/dLSerum aspartate aminotransferase (AT) (1-35 LU/dL)81/LLAlanine aminotransferase (AT) (7-35 LU/dL)91/LLAlumin (3.5-5.0 g/dL)6.9 g/dLTriglyceride (s 150 mg/dL)6.9 g/dLLipase (240 LU/dL)1.9 g/dLLipase (240 LU/dL)1.9 g/dLAnylase (261 LU/dL)5.1 L/LSerum calu (ML)5.1 L/LSerum calu (ML)6.1 g/dL   | Lymphocytes  | 38%        |
| Esinophis2%Patelet (140,00-400,00µL)32,00µLTota bilrub (12,0mg,0L)0,0mg,0LTota bilrub (12,0mg,0L)12,0mg,0LPatena manotansfera (ATC) (13,0mg,0L)81,0LAlanie nahos (AL) (13,0mg,0L)13,0mg,0LAlumi (3,5-5,0gL)36,0LTigverde (13,0mg,0L)13,0mg,0LLipase (20,0L)10,2LAnyae (20,1DU/L)10,1LSem (14,0mg,0L)10,1LSem (14,0mg,0L)11,1LSem (14,0mg,0L)11,1LSem (14,0mg,0L)11,1LSem (14,0mg,0L)11,1LSem (14,0mg,0L)11,1L  | Monocytes  | 9%         |
| Platelets (140,000-400,00µL)Siz,00µLTotal bilirubin (≤ 1.2 mg/dL)0.9mg/dLDirect bilirubin (≤ 0.5 mg/dL)0.12 mg/dLSerum aspartate aminotransferase (AST) (13-35 IU/dL)8I U/LAlanine aminotransferase (ALT) (7-35 IU/dL)8I U/LAlkaline phosphatase (ALT) (7-35 IU/dL)98 U/LAlubin (3.5-5.0 g/dL)36 g/dLTriglyceride (≤ 150 mg/dL)36 g/dLLipase (≤ 201 U/L)1.02 IU/LAnylase (20-110U/L51 IU/LSerum calcium (9.0-13.8 mg/dL)51 IU/L  | Eosinophils  | 2%         |
| Total biling in (2 , 2 m) of (2 m)Omega (2 m)Direct biling in (2 , 2 m)Direct (2 m)Serum aspartate aminotransferase (AST) (1 - 3 m)Direct (2 m)Alanine aminotransferase (AST) (1 - 3 m)Direct (2 m)Alanine about (2 m)Direct (2 m)Alumin (3.5-5.0 , 2 m)Direct (2 m)Trighceride (1 m)Direct (2 m)Index (2 m)Direct (2 m)Anyase (2 m)Direct (2 m)Anyase (2 m)Direct (2 m)Serum (2 m)Direct (2 m)   | Platelets (140,000-400,000/µL)   | 352,000/μL |
| Direct bilrubin (≤ 0.25 mg/dL)0.12 mg/dlSerum aspartate aminotransferase (AST) (3-55 U/dL)67Alanien aminotransferase (ALT) (7-35 U/dL)88 U/LAladine phosphatase (64-300 U/dL)180 U/dLAlbumin (3-5-5.0 g/dL)3.6 g/dLTrigtoeride (≤ 150 mg/dL)13.0 mg/dLLipase (≥ 200 U/L)1.0 22 U/LAmylase (20-110U/L)1.5 U/LSerum calcum (B, C)6.4 mg/dL   | Total bilirubin (≤ 1.2 mg/dL)  | 0.9mg/dL   |
| Serun aspartate aminotransferase (AST) (13-35 IU/dL)67Alanine aminotransferase (ALT) (7-35 IU/dL)81 /ULAkaline phosphatase (64-300 IU/dL)198 /ULAbumin (3.5-5.0 g/dL)36 g/dLTrigloceride (5150 mg/dL)103 mg/dLLipase (200 IU/L)102 IU/LAmylase (20-110U/L)11 IU/LSerun calcium (9.6-10.8 mg/dL)84 mg/dL  | Direct bilirubin (≤ 0.25 mg/dL)  | 0.12 mg/dl |
| Alanine aminotransferase (ALT) (7-35 IU/dL)88 IU/LAlkaline phosphatase (64-300 IU/dL)198 U/dLAlbumin (3.5-5.0 g/dL)3.6 g/dLTriglyceride (≤150 mg/dL)133 mg/dLLipase (≤200 IU/L)1.022 IU/LAmylase (20-110U/L51 IU/LSerum calcium (9.0-10.8 mg/dL)8.4 mg/dL  | Serum aspartate aminotransferase (AST) (13-35 IU/dL)   | 67         |
| Akaine phosphatase (64-300 IU/dL)198 U/dLAbumin (3.5-5.0 g/dL)3.6 g/dLTriglyceride (±150 mg/dL)133 mg/dLLipase (±200 IU/L)1.022 IU/LAmylase (20-110U/L)151 IU/LSerum calcium (9.0-10.8 mg/dL)8.4 mg/dL   | Alanine aminotransferase (ALT) (7-35 IU/dL)  | 88 IU/L    |
| Abumin (3.5-5.0 g/dL)   3.6 g/dL     Triglyceride (± 150 mg/dL)   133 mg/dL     Lipase (± 200 IU/L)   1,022 IU/L     Amylase (20-110U/L   151 IU/L     Serum calcium (9.0-10.8 mg/dL)   8.4 mg/dL  | Alkaline phosphatase (64-300 IU/dL)  | 198 U/dL   |
| Triglyceride (≤ 150 mg/dL) 133 mg/dL   Lipase (≤ 200 IU/L) 1,022 IU/L   Amylase (20-110UI/L 151 IU/L   Serum calcium (9.0-10.8 mg/dL) 84 mg/dL   | Albumin (3.5-5.0 g/dL)   | 3.6 g/dL   |
| Lipase (≤ 200 IU/L) 1,022 IU/L   Amylase (20-110UI/L 151 IU/L   Serum calcium (9.0-10.8 mg/dL) 8.4 mg/ dL  | Triglyceride (≤ 150 mg/dL)   | 133 mg/dL  |
| Amylase (20-110UI/L   151 IU/L     Serum calcium (9.0-10.8 mg/dL)   8.4 mg/ dL   | Lipase (≤ 200 IU/L)  | 1,022 IU/L |
| Serum calcium (9.0-10.8 mg/dL) 8.4 mg/ dL  | Amylase (20-110UI/L  | 151 IU/L   |
|  | Serum calcium (9.0-10.8 mg/dL)   | 8.4 mg/ dL |

### **TABLE 1: Clinical laboratory findings**

The patient was diagnosed with acute respiratory distress syndrome (ARDS) with severe acute pancreatitis secondary to COVID-19 infection and as a result, was admitted to the intensive-care unit. The patient was managed and treated with intravenous fluids, fasting, and total parenteral nutrition, antibiotics, antiemetics, and analgesics. Axial CT image of the abdomen was notable for interstitial edema of the pancreas with the homogenous enhancement of the pancreatic parenchyma and mild inflammatory changes (fat stranding) surrounding the pancreas (Figure 1). Supportive therapy continued, and improved clinical condition was observed after three days of treatment. The patient's oxygen saturation improved drastically (97% on room air) and no longer required oxygen therapy. The patient was discharged from the hospital after clinical improvement of symptoms.



FIGURE 1: Abdominal CT scan showing interstitial edema of the pancreas with the homogenous enhancement of the pancreatic parenchyma and mild inflammatory changes (fat stranding)

# **Discussion**

In late December 2019, the WHO China County office reported a number of pneumonia cases of unknown cause observed in Wuhan City, China. This, of course, resulted in major investigations and the confirmation of the novel coronavirus as the primary cause of an outbreak. The World Health Organization announced an official name for the disease on February 11, 2020. This important milestone marked the beginning of a global emergency and pandemic. To date, the SARS-CoV-2 has continued to have a catastrophic impact on international relations, global health, global network in production, social networking, economy, and approximately 50 million people worldwide [5, 6]. Typically, patients infected with COVID-19 present with classical presentations of respiratory symptoms such as a cough, dyspnea, fever, and pharyngitis. However, we continue to discover new extrapulmonary manifestations. The severity of COVID-19 is typically combined with a set of comorbid conditions such as diabetes, hypertension, cardiovascular disease, advanced age, and obesity. Furthermore, infected patients can present with atypical symptoms related to the gastrointestinal system. One study, in particular, indicated that COVID-19 patients experienced gastrointestinal symptoms such as diarrhea (24.2%), anorexia (17.9%), and nausea (17.9%) [7].

About 10% of pancreatitis cases are thought to be directly caused by infectious microorganisms such as parasites, bacteria, and viruses [8]. Viral pancreatitis has been widely reported in medical literature to be most commonly caused by mumps, viral hepatitis, coxsackieviruses, echoviruses, and mycoplasma [9]. The mechanism of the relation with the development of pancreatitis associated with COVID-19 infection is unknown and multifactorial. For example, several factors may contribute to the development of pancreatitis, including premature activation and autodigestion of pancreatic enzymes and microcirculatory disturbance of the pancreas. Theoretical explanations for the association between COVID-19 and pancreatitis include cellular overexpression of the angiotensin-converting enzyme 2 (ACE2), a molecular target for SARS-CoV-2 [10]. Additionally, extrapulmonary manifestations of fulminant myopericarditis secondary to COVID-19 infection have been reported [11]. The reported case demonstrated the possible correlation between COVID-19 and nonspecific gastrointestinal symptoms, life-threatening ARDS, and myopericarditis. Based on our case above, the established diagnosis of pancreatitis in this patient appears to be idiopathic due to the patient's lack of comorbid conditions, history of alcohol abuse, or trauma. It is worth noting that there is a possible correlation between COVID-19 infection and acute pancreatitis. However, there is insufficient evidence to link COVID-19 directly to acute pancreatitis as a causative agent, and further studies need to be conducted to evaluate the possible correlation.

# Conclusions

This case of a 30-year-old male patient demonstrates that COVID-19 infection can cause nonspecific gastrointestinal symptoms and acute pancreatitis. The diagnosis of COVID-19 was established by utilizing

PT-PCR. Additionally, abnormal lipase, amylase enzyme levels were obtained, and CT scan findings were all indicative of acute pancreatitis. We encourage medical practitioners to carefully and meticulously evaluate gastrointestinal symptoms in patients with active COVID-19 patients in order to prevent delays in diagnosis and treatment.

# **Additional Information**

#### Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

# References

- 1. Samuel JC, Ludzu EK, Cairns BA: A case of acute necrotizing pancreatitis: Practical and ethical challenges of a North-South partnership. Int J Surg Case Rep. 2013, 4:1130-1133. 10.1016/j.ijscr.2013.10.009
- 2. Banks PA: Acute pancreatitis: medical and surgical management. Am J Gastroenterol. 1994, 89:78-85.
- Beger HG, Rau BM: Severe acute pancreatitis: clinical course and management. World J Gastroenterol. 2007, 13:5043-5051. 10.3748/wjg.v13.i38.5043
- Song Y, Liu P, Shi XL: SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020, 69:1143-1144. 10.1136/gutjnl-2020-320891
- Novel Coronavirus (2019-nCoV) situation reports World Health Organization . (2020). Accessed: 2020: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
- Majumder MS, Mandl KD: Early transmissibility assessment of a novel coronavirus in Wuhan, China . SSRN. 2020, 10.2139/ssrn.3524675
- Lin L, Jiang X, Zhang Z: Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020, 69:997-1001.
- Forsmark CE, Swaroop Vege S, Wilcox CM: Acute pancreatitis. N Engl J Med. 2016, 375:1972-1981. 10.1056/NEJMra1505202
- 9. Parenti DM, Steinberg W, Kang P: Infectious causes of acute pancreatitis. Pancreas. 1996, 13:356-371. 10.1097/00006676-199611000-00005
- Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q: Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020, 159:367-370. 10.1053/j.gastro.2020.03.055
- Hussain H, Fadel A, Alwaeli H, Guardiola V: Coronavirus (COVID-19) fulminant myopericarditis and acute respiratory distress syndrome (ards) in a middle-aged male patient. Cureus. 2020, 12:e8808. 10.7759/cureus.8808